Thus, AChE inhibitors with dual binding sites will not only stimulate the cholinergic system to alleviate cognitive deficits in AD patients, but also inhibit the production or aggregation of Aβ (Castro and Martinez 2006). Here, ACHE is linked to Alzheimer disease.